Projects & Grants
| Therapeutic monitoring of serum concentrations of the active metabolite of leflunomide in patients with rheumatoid and psoriatic arthritis | |
|---|---|
| Project Id | |
| Main solver | MUDr. Katarína Balošáková |
| Period | 1/2025 - 12/2025 |
| Provider | Specifický VŠ výzkum |
| State | solved |
| Anotation | Leflunomide belongs to the disease-modifying antirheumatic drugs (DMARDs) with antiproliferative properties, used in the treatment of rheumatoid arthritis and psoriatic arthritis. In vivo, it is rapidly and almost completely metabolized into its active metabolite, teriflunomide. Unfortunately, the response to leflunomide treatment is variable, and therapeutic failure has been observed in a significant portion of patients. To minimalize the risk of adverse effects and optimalize the drug dosage for individual patients, therapeutic drug monitoring (TDM) can be used. TDM is a specialized method in the field of clinical pharmacology, used to monitor pharmacotherapy by determining the concentration of a drug in the blood. The aim of the project will be a retrospective analysis of the relationship between measured serum concentrations of teriflunomide in patients from the rheumatology outpatient clinic of FNO and both therapeutic efficacy and adverse effects. This could help optimalize and individualize the treatment of rheumatoid and psoriatic arthritis through therapeutic drug monitoring. |
